- Home
- Dr Hsieh Wen-Son
Dr Hsieh Wen-Son
Dr Hsieh Wen-Son
Medical Oncology
Sub-specialty Interests: Lymphoma, head and neck and lung cancers and hepatobiliary cancers.
BSC (USA), MD (USA), Internal Medicine (USA), Medical Oncology (USA), Diplomate Internal Medicine and Medical Oncology ABIM (USA)
- Video Consult
- Clinic Visit
1 Farrer Park Station Road, #09-13 Connexion, Singapore 217562
Languages:
English, Mandarin
About Dr Hsieh Wen-Son
With extensive clinical and research experience spanning 30 years, Dr Hsieh Wen Son is specialised in the treatment of various types of cancers and is active in developing novel cancer diagnostics and molecularly targeted anti-cancer treatments. After studying Philosophy and Psychology at Oxford University on a Rhodes Scholarship, Dr Hsieh obtained his medical degree from Johns Hopkins University. He then completed training in Internal Medicine at Duke University and in Medical Oncology/Hematology at Johns Hopkins. During his post-doctoral training, Dr. Hsieh trained in the laboratory of Prof. Richard Ambinder, where he performed laboratory and clinical research regarding the role of Epstein-Barr virus in lymphomas and other cancers. Upon completion of his training, Dr Hsieh was active in patient care, teaching, and research as a full time faculty member at the Johns Hopkins University School of Medicine in the Division of Hematologic Malignancies.
After entering private practice, he remained a part time Assistant Professor at Johns Hopkins University and a Principal Associate at the Cancer Sciences Institute of Singapore at the National University of Singapore, where he was active in the development of novel tests and treatments to diagnose and treat cancer. He continues to be active in the conduct and oversight of clinical trials in his roles as the Chair of the Research Committee for ICON Cancer Centres Singapore and the Deputy Chairman of a National Healthcare Group (NHG) Domain Specific Review Board (DSRB).
With a research interest in molecularly targeted cancer therapies, immunotherapy and molecular diagnostics, Dr Hsieh has led multiple international studies involving centres in Singapore, Hong Kong, Korea, Myanmar, the Philippines, and the United States examining novel treatments and novel diagnostic tests for lymphomas, nasopharyngeal and hepatocellular carcinoma. He has also been the principal investigator of more than forty completed or ongoing clinical trials investigating novel treatments for lung cancer, breast cancer, gastrointestinal cancers, and blood cancers. Dr Hsieh has authored over 80 scientific articles, abstracts, and book chapters and has lectures frequently at regional and international medical and scientific conferences. Dr Hsieh is committed to providing evidence-based treatment for current cancer patients as well as to developing more effective cancer treatments through clinical research.
Dr Hsieh accepts referrals for all cancer types, with a special clinical interest in lymphoma, head and neck and lung cancers as well as hepatobiliary cancers.
Affiliations & Memberships
- Member of American Association of Cancer Research (AACR)
- Chair of the Research Committee for Icon Cancer Centres Singapore
- Deputy Chairman of National Healthcare Group (NHG) Domain Specific Review Board (DSRB).
Publications
- Cytidine Methylation of Regulatory Sequences Near the Pi-Class Glutathione S-Transferase Gene Accompanies Human Prostatic Carcinogenesis. Lee, W.H, Morton, R.A, Epstein, J.I., Brooks, J.D., Campbell, P.A., Bova, G.S., Hsieh, W.S., Isaacs, W.B., and Nelson, W.G. Natl.Acad. Sci. 1994; 91 (24): 11733-11737.
- Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer. Hsieh, WS, Soo, RA, Peh, BK, Loh, T, Dong, DF, Soh, D, Wong, LS, Green, SR, Chiao, JT, Cui, CY, Lai, YF, Lee, SC, Mow, B, Soong, R., Salto-Tellez, M, Goh, BC. Clinical Cancer Research 2009; 15(4): 1435-42.
- A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Low, SW, Tao, Q*, Ng, KM, Goh, HK, Shu, XS, Ambinder, RF, Srivastava, G, Shamay, M, Chan ATC, Popescu, NC, Hsieh, WS*. Oncogene 2011; 30(16): 1923-1935. *Co-Corresponding Author.
- Plasma Epstein-Barr virus DNA as a marker of tumor response in Hodgkin lymphoma. Kanakry, JA, Li, HL, Gellert, LL, Lemas, MV, Hsieh, WS, Hong, FX, Tan, KL, Gascoyne, RD, Gordon, LI, Fisher, RI, Bartlett, NL, Stiff, P, Cheson, BD, Advani, R, Miller, TP, Kahl, BS, Horning, SJ, Ambinder, RF. Blood 2013; 121 (18): 3547-3553.
- Methylation in cell-free Epstein-Barr virus DNA in patients with EBV+ Hodgkin lymphoma. Shamay, M, Kanakry, JA, Low, JSW, Horowitz, NA, Journo, G, Ahuja, A, Yontan, E, Elinor B, Eldad JD, Stone J, Woo WL, Hsieh WS, Xian R, Ambinder RF. Blood Advances 28;4(8):1624-1627, 2020
- Kuss B, Nagarajan C, Hsieh WS, Cheah CY. Practical management of chronic lymphocytic leukemia with acalabrutinib. Leuk Lymphoma. 2022 Dec;63(12):2785-2794.
Book an Appointment
Make a booking for an In-Clinic Visit or Teleconsult (local or overseas). It is important to note that teleconsult is used for non-emergency advice and to receive consult on elective treatment.